paclitaxel

The largest series of femoropopliteal in-stent restenosis to date 

Original title:&nbsp;Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX.&nbsp;Reference:&nbsp;Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274&ndash;81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length.&nbsp; The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook<a href="https://solaci.org/en/2013/04/08/n-2829/" title="Read more" >...</a>

Rotational atherectomy is only an interim strategy.

Original title:&nbsp;High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions. The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial.&nbsp;Reference:&nbsp;Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2013; article in press Heavily calcified lesions are difficult and may prevent the appropriate expansion of a<a href="https://solaci.org/en/2013/01/04/n-3137/" title="Read more" >...</a>

Future strategies to prevent restenosis and stent thrombosis

Original title:&nbsp;Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification.&nbsp;Reference:&nbsp;Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as<a href="https://solaci.org/en/2012/12/04/n-3277/" title="Read more" >...</a>

Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title:&nbsp;Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia&nbsp;Reference:&nbsp;Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory.&nbsp; The use<a href="https://solaci.org/en/2012/11/30/n-3837/" title="Read more" >...</a>

A new paradigm in the treatment of in-stent restenosis?

Original title:&nbsp;ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents&nbsp;Reference:&nbsp;Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or<a href="https://solaci.org/en/2012/11/11/n-3746/" title="Read more" >...</a>

Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery

Original title:&nbsp;Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis&nbsp;Reference:&nbsp;Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739&ndash;42 (2012) Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery&nbsp; This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent<a href="https://solaci.org/en/2012/11/09/n-3739/" title="Read more" >...</a>

Diabetics with multivessel, must keep waiting.

Original title:&nbsp;Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial.&nbsp;Reference:&nbsp;Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries &gt; 70%<a href="https://solaci.org/en/2012/11/08/n-3732/" title="Read more" >...</a>

Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents

The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,<a href="https://solaci.org/en/2012/10/01/n-3935/" title="Read more" >...</a>

Top